Entrada Therapeutics, Inc. (TRDA) Tops Q4 EPS by 4c

Entrada Therapeutics, Inc. (NASDAQ: TRDA) reported Q4 EPS of ($0.94), $0.04 better than the analyst estimate of ($0.98). Revenue for the quarter came in at $1.3 million versus the consensus estimate of $5.81 million.

For earnings history and earnings-related data on Entrada Therapeutics, Inc. (TRDA) click here.

You May Also Be Interested In

• Deere conference call: 2027 orders up mid-single digits from last year)
• Bernstein upgrades Analog Devices on Q3 beat, improving risk-reward
• Twin Disc (TWIN) Tops Q4 EPS by 16c